OCT 25, 2017 06:00 AM PDT

WEBINAR #3: Enabling neurological disease research via DNA fragment analysis on the new SeqStudio genetic analyzer

SPONSORED BY: Thermo Fisher Scientific
C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Senior Vice President, Research and Development, Asuragen
      Dr. Gary Latham is Senior Vice President of R&D for Asuragen, a molecular diagnostics company focused on genetics and oncology. Gary joined Asuragen when it was founded in 2006, and currently oversees the company's research, assay development, partnered R&D, and bioinformatic teams. He guided the development of AmplideX® PCR technology for fragile X syndrome and other DNA repeat disorders, and DNA- and RNA-based QuantideX® NGS products for oncology applications. Gary is an inventor on 12 issued US patents, has received >$13M in research grants from the NIH and the Cancer Prevention and Research Institute of Texas (CPRIT), and has authored >40 peer-reviewed publications.


    DATE: October 25, 2017
    TIME: 06:00am PDT, 09:00am EDT

    This is the third topic in the webinar series on ‘Sanger Sequencing & Fragment Analysis made easy’.

    Repetitive DNA sequences comprise half of the human genome and include at least 1.6 million short tandem repeats with dark functions and unknown disease implications. Recent genome-wide studies have illuminated thousands of associations of such repeat elements with changes in gene expression. In addition, over 30 Mendelian disorders are known to be caused by triplet repeat expansions. Thus there is a rapidly growing appreciation that repetitive “dark” DNA is discoverable, discernible and diagnostic.

    In this webinar, we will discuss:

    • How reliable, long-read AmplideX® PCR technology can be combined with the SeqStudio Genetic Analyzer to operationalize the routine detection of established and emerging repeat DNA markers in an easy-to-use assay system
    • Data showing sensitive and accurate analyses of GC- and AT-rich repeat expansions and length polymorphisms associated with Fragile X Syndrome, ALS/FTD, Myotonic Dystrophy, Huntington’s Disease, and Alzheimer Disease
    • The implications of high-resolution repeat DNA genotyping for scientific and clinical research of neurodevelopmental, neurodegenerative, and neuromuscular disorders

    Other topics in the webinar series:

    Show Resources
    Show Resources
    Connect with us